Research Nester assesses the growth of global preeclampsia diagnostics market which is anticipated to be on account of the growing prevalence of preeclampsia in pregnant women across the globe.

New York – March 22, 2023 - Research Nester’s recent market research analysis on “Preeclampsia Diagnostics Market: Global Demand Analysis & Opportunity Outlook 2035” delivers a detailed competitors analysis and a detailed overview of the global preeclampsia diagnostics market in terms of market segmentation by test type, product type, end-users, and by region.

Growing Maternity Age over the Past Decade to Drive Growth of Global Preeclampsia Diagnostics Market

Past decade has witness significant rise in maternal age from over 25-35 to 40-45 years old. The high maternal age is directly related to gestational diabetes, hypertension, and other severe complexities in pregnancy. In addition, the shift in lifestyle to a busier schedule with huge responsibilities at work has directly led to delaying of childbearing age. Advanced maternity age had a significant indirect effect (mediated effect) on preterm delivery and low birth weight, which was mediated by preeclampsia. Therefore, in order to avoid such changes in the occurrence of preeclampsia and to be assisted with the correct decision-making in childbearing, women must be counselled appropriately during antenatal visits. As per the reported data, the estimated mediation proportion of the effect of advanced maternity age in consideration of preeclampsia's mediated effect was (35.5%) for preterm delivery and (23.5%) for low birth weight.

Some of the major growth factors and challenges that are associated with the growth of the global preeclampsia diagnostics market are:

Growth Drivers:

• Growing awareness of the benefits of early pregnancy screening test
• Regulations supporting the preeclampsia diagnostics

Challenges:

Lack of awareness regarding the prevalence of preeclampsia in several countries is a major factor anticipated to hamper the growth of the global preeclampsia diagnostics market. For instance, a study assessed the level of knowledge of preeclampsia and evaluated the factors associated with knowledge adequacy among pregnant women in 2019. This cross-sectional examination was executed at the University Hospital in Kumasi, Ghana. The validated closed-ended questionnaire suggested that the prevalence of inadequate and adequate knowledge of preeclampsia was 88.6% and 11.4%, respectively. For participants with adequate knowledge of preeclampsia, 9.1% and 2.3% had moderate and high knowledge, respectively. In addition, being older and having a higher level of education were found to be particularly associated with greater chances of having adequate knowledge of preeclampsia. Therefore, all these factors are expected to restrain the market’s growth over the forecast period.

The study concluded that the knowledge of preeclampsia among pregnant women in Ghana is low. A higher level of education is the prominent factor that facilitates the adequacy of knowledge of preeclampsia.

By product type, the global preeclampsia diagnostics market is segmented into instruments and consumables. The consumables segment is expected to garner the highest revenue by the end of 2035 by growing at a significant CAGR of 10.24 % over the forecast period. Consumables used in the healthcare industry are regularly replaced after one use. The types of consumables include plasticware, glassware, general lab supplies, tubes, strips, filters, kits, reagents, caps, tips, gloves, and others. As consumables are for one-time usage, automatically the demand for reagents, kits, and others increases. The volume of the consumables is exclusively higher than the instruments in the healthcare facilities. Therefore, it is projected to boost the growth of the segment over the forecast period.

By region, the North America preeclampsia diagnostics market is to generate the highest revenue by the end of 2035. Moreover, the market’s revenue is predicted to grow from USD 500.5 Million in the year 2022 to USD 1262.0 Million in the year 2035. This growth is anticipated by strong healthcare infrastructure and prevalence of the disease in the region. A survey from 2021 underscores the stark need for more education about preeclampsia as the second-most common cause of maternal mortality in the US. The survey of nearly 800 women conducted by Progenity, Inc. showed that less than half of respondents know that high blood pressure is the main sign and is a key indicator of preeclampsia. Moreover, the condition is often missed or misdiagnosed using current methods owing to the symptoms are common and non-specific, which collectively affects the growth of the preeclampsia diagnostic market in the region.

This report also provides the existing competitive scenario of some of the key players of the global preeclampsia diagnostics market which includes company profiling of F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Diabetomics, Inc., Thermo Fisher Scientific Holdings, Inc., Metabolomic Diagnostics, DRG Instruments GmbH, Siemens Healthineers AG, Sera Prognostics, Inc., and Shuwen Biotechnologies Co., Ltd., and others.